Key result
DNMT inhibitors may slow diabetic retinopathy progression by modulating BDNF gene expression.
Why the study?
Understanding epigenetic modifications in type II diabetic retinopathy has the potential to identify novel targets, such as DNMT inhibitors, to prevent or slow disease progression.
Epigenetic modifications, particularly DNA methylation, play a role in type II diabetic retinopathy, and DNMT inhibitors may offer a personalized medicine approach by modulating BDNF gene expression.
DNMT inhibitors merit investigation in diabetic retinopathy; leaves open confirmation of BDNF-mediated benefit in trials.
Type II diabetic retinopathy is one of the familiar problems of diabetes which is considered by differences in retinal blood vessels. Epigenetic modifications participates vital role in various diseases such as diabetic retinopathy is nowadays a rising area. Numerous possibilities for treatment of diabetic retinopathy through epigenetic modification have been studied in various review articles. With the increasing proof of epigenetic modifications in case of diabetic retinopathy, better consideration of these modifications has latent to recognize novel targets to prevent this disease. The Dnmt inhibitors (DNA methyltransferase), 5-aza-20-deoxycytidine and 5-azacytidine together have been agreed by the FDA. More distant studies have observed that the reaction of those compounds on diabetic retinopathy where in they appear to slow down the process of methylation with few favourable outcome at decreasing the symptoms. Some demethylating agents may be favourable in the treatment of diabetic retinopathy. So, the effects of demethylating agents can be used to check the expression levels of BDNF gene and if they give better results then it may use as personalized medicine in future to block or slow down the progression of type II diabetic retinopathy.
No takes yet. Share an insight, caveat, or question.
Lucky Buragohain (2019) conducted a review in Type-2 Diabetic Retinopathy. DNMT Inhibitors (5-aza-20-deoxycytidine and 5-azacytidine) was evaluated. Demethylating agents such as DNMT inhibitors may be useful in the treatment of diabetic retinopathy by modulating the expression levels of genes like BDNF to slow down disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: